—Case Reports—

Ritodrine-induced Pustular Eruptions Distinctly Resembling Impetigo Herpetiformis

Yoshimitsu Kuwabara1,2, Atsuki Sato1,2, Hiroko Abe1,2, Sumino Abe1, Naoki Kawai1 and Toshiyuki Takeshita1

1Department of Obstetrics and Gynecology, Tokyo Rinkai Hospital, Tokyo
2Division of Reproductive Medicine, Perinatology and Gynecologic Oncology, Graduate School of Medicine, Nippon Medical School
3Department of Dermatology, Tokyo Rinkai Hospital, Tokyo

Abstract

A 27-year-old nulligravida woman without a history of dermatosis was hospitalized for threatened preterm labor at 29 weeks’ gestation; therefore, continuous infusion of ritodrine hydrochloride was started. At 31 weeks’ gestation, erythematous plaques appeared and spread over the body surface; therefore, a topical steroid preparation was applied. At 32 weeks’ gestation, the eruptions developed into irregular annular areas of erythema with multiple pustules accompanied by severe itching, and oral prednisolone treatment was started. Bacterial cultures of the pustules were negative, and a crural cutaneous biopsy revealed Kogoj’s spongiform pustules. Based on the clinicopathological findings, the most likely diagnosis was impetigo herpetiformis, which causes cutaneous symptoms closely resembling pustular psoriasis in pregnant females without a history of psoriasis. To rule out ritodrine-induced pustular eruptions, the ritodrine infusion was stopped and treatment with an MgSO4 preparation was started at 33 weeks’ 3 days’ gestation; however, the uterine contractions could not be suppressed. Because of the patient’s highly edematous, severely painful feet, a cesarean section was performed the same day. Within several days of delivery, the eruptions began to resolve, and no recurrence was observed after treatment with oral prednisolone was stopped 31 days after delivery. On the basis of a positive patch test for ritodrine, we diagnosed pustular drug eruptions caused by ritodrine hydrochloride. Although ritodrine-induced pathognomonic cutaneous eruptions are rare, we would like to emphasize that ritodrine can cause drug-induced pustular eruptions distinctly resembling life-threatening impetigo herpetiformis.

(J Nippon Med Sch 2011; 78: 329–333)

Key words: pustular eruptions, ritodrine hydrochloride, impetigo herpetiformis
Introduction

Ritodrine hydrochloride has been used to treat preterm uterine contractions for more than 15 years. The major side effects of ritodrine are palpitations, tachycardia, tremors, nausea, hypopotassemia, transient hypoglycemia, vasculitis vascular pain, and flushing1. In some cases, more serious side effects occur, including cardiac arrhythmia, myocardial ischemia, pulmonary liver dysfunction, and neutropenia. Ritodrine administration also induces benign rashes in 1% to 3% of treated patients2; however, few cases of pathognomonic cutaneous eruptions, including maculopapular rash3, cutaneous vasculitis4, and erythema multiforme-like lesions5, have been reported. We report a case of ritodrine-induced pustular eruptions in a pregnant woman without a history of skin eruptions, which distinctly resembled life-threatening impetigo herpetiformis (IH).

Case

A 27-year-old nulligravida woman was hospitalized for threatened preterm labor at 29 weeks’ gestation. The personal and family histories were negative for skin diseases, including psoriasis. Transvaginal ultrasonography revealed a shortened uterine cervix, 24 cm in length, and contractions were occurring every 5 minutes. Bacterial culture of the vaginal discharge collected at this time demonstrated normal Lactobacillus flora. She was given intravenous ritodrine hydrochloride (Utenerin; Kissei Pharmaceutical Co., Ltd., Matsumoto, Japan) at 50 μg/min in a 5% glucose solution. The dosage was gradually increased to 125 μg/minute over 15 days, and the contractions abated. At 31 weeks’ gestation (17 days after admission), the patient complained of pruritus and a rash around the forearm site of intravenous infusion. The infusion site was changed, and the rash resolved. The next day, erythematous plaques appeared on the face, arms, and abdomen, and a topical steroid preparation was applied. At 32 weeks’ gestation (25 days after admission), numerous tiny nonfolicular pustules appeared on the erythematous plaques (Fig. 1). The laboratory findings were normal, including those for the white blood cell count, hematocrit, platelet count, electrolyte determinations, liver function test, and C-reactive protein value. Bacterial pustule cultures collected at this time were negative. An oral steroid preparation was started at a dosage of 10 mg/day; however, the erythema worsened and spread to the back, chest, abdomen, and extremities within several days. The dosage of the oral steroid preparation was increased to 20 mg/day at 33 weeks’ gestation (29 days after admission).

A crural cutaneous biopsy revealed subcorneal neutrophilic pustules forming spongiform structures, a finding consistent with Kogoji’s spongiform pustules (Fig. 2). Based on the clinicopathological findings, the most likely diagnosis was IH, a type of eruption closely resembling pustular psoriasis that develops in pregnancy. There was also a concern that the administered ritodrine might have caused drug-induced pustular eruptions. To rule out ritodrine-induced pustular eruptions, we discontinued the administration of ritodrine and started treatment with MgSO4 at 1 g/hour at 33 weeks’ 3 days’ gestation (32 days after admission). The frequency of uterine contractions gradually increased, and after several hours the dosage of MgSO4 was increased to 2 g/hour. A fever developed (maximum temperature: 37.5°C), as did marked inflammatory bilateral edema of the lower thighs accompanied by severe pain.

Laboratory examinations showed leukocytosis (15,950 × 10⁹/L) with significant neutrophilia (60%), an increased level of C-reactive protein (7.18 mg/dL), and hypoalbuminemia (3.0 g/dL). The other laboratory findings and systemic conditions were unremarkable. The body surface was covered by areas of erythema and multiple pustules, some of which had formed an irregular annular configuration accompanied by repeated partial regression and regeneration (Fig. 3). Some of the pustules on the thighs and back had coalesced into larger pus-filled bullae.

Because of the difficulty of controlling the preterm uterine contractions and the acute development of
Ritodrine-induced Pustular Eruptions

![Fig. 1](image1.png)

**Fig. 1** Numerous tiny nonfollicular pustules appeared on the erythematous plaques.

![Fig. 2](image2.png)

**Fig. 2** Histologic examination revealed subcorneal neutrophilic pustules forming spongiform structures, consistent with Kogoj’s spongiform pustules.

![Fig. 3](image3.png)

**Fig. 3** The patient's body was covered with pustular eruptions, partly forming irregular annular configurations.

![Fig. 4](image4.png)

**Fig. 4** Four concentrations of ritodrine solution (1%, 0.1%, 0.05%, and 0.01%) and distilled water as a control were applied to the skin of the back and checked after 48 and 72 hours. The results were clearly positive at every concentration of the solution at both 48 and 72 hours after application.

Eruptions accompanied by systemic inflammation, we finally decided to resolve the pregnancy. Owing to the severe edema and pain of the thighs, emergency cesarean section was chosen as the delivery mode. A 1.945-g male infant was delivered and transported to the local neonatal intensive care unit because of low birth weight and transient tachypnea. Within several days of delivery, the eruptions began to resolve. The administration of the oral steroid preparation was tapered in a stepwise fashion and finally stopped 31 days after delivery. Forty-one days after delivery, no pustular eruption was observed, although areas of irregular annular erythema remained on parts of the back and extremities.

A patch test was performed to confirm whether the pustular eruptions had been caused by ritodrine. Four concentrations of ritodrine solution (1%, 0.1%, 0.05%, and 0.01%) and distilled water as a control were applied to the skin of the back and checked after 48 and 72 hours. No other drugs other than ritodrine were tested, because ritodrine was the only drug that had been administered before the pustular eruptions appeared. The results were clearly positive at every concentration of the solution at both 48 and 72 hours after application (**Fig. 4**). We also patch-tested 10 women volunteers without a history of ritodrine use. No positive reactions to ritodrine were observed in this group, supporting...
the conclusion that the patient’s reaction to ritodrine was allergic rather than toxic. On the basis on these results, pustular eruption caused by ritodrine hydrochloride was diagnosed.

**Discussion**

Ritodrine hydrochloride is a beta-adrenergic stimulant with predominant effects on the beta 2 receptor used to avoid abortion and preterm delivery. Several cases of ritodrine-induced pathognomonic cutaneous eruptions have been reported; however, only a single case of pustular eruptions related to ritodrine has been reported, in a pregnant woman with psoriasis. It should be noted that all reported cases, including the present case, exhibited skin eruptions more than several weeks after the start of drug treatment.

In the present case, the clinicopathological findings fulfilled the diagnostic criteria of pustular psoriasis; therefore, we initially suspected IH, which has cutaneous symptoms closely resembling pustular psoriasis in pregnant women without a history of psoriasis. IH is a rare dermatosis of pregnancy that can present in the third trimester with widespread cutaneous pustulosis and severe systemic features. Early recognition is important because this condition is life threatening, and misdiagnosis and inappropriate treatment may compromise maternal and fetal well-being. IH is associated with increased fetal morbidity and with complications, such as stillbirth, placental insufficiency, fetal growth restriction, preterm labor, and neonatal death. Because few drugs can be used during pregnancy, systemic corticosteroids are the main treatment for this condition.

Besides pustular psoriasis, major dermatoses that should be differentiated from drug-induced pustular eruption are acute generalized exanthematous pustulosis (AGEP), pustulosis acuta generalisata (PAG), and subcorneal pustular dermatosis (SPD). AGEP is a rare severe cutaneous adverse reaction most often caused by drugs which is characterized by fever, neutrophilia, and acute, extensive formation of nonfollicular sterile pustules on an erythematous background. AGEP has also been reported in pregnant patients. The development of cutaneous symptoms in AGEP is almost always accompanied by fever greater than 38°C, and pustules usually resolve spontaneously within several days. In the present case, a fever developed on the last day of the patient’s pregnancy; however, the acute exacerbation of erythema was not accompanied an increase in body temperature. Furthermore, the morphology of the erythema, which developed irregular annular configurations with repeated partial regression and regeneration, was also distinct from that of AGEP.

PAG is a poststreptococcal disease that has been reported in association with streptococcal vaginitis. In the present case, bacterial culture of the vaginal discharge demonstrated normal Lactobacillus flora, suggesting that the patient’s condition was not associated with PAG.

SPD, also known as “Sneddon-Wilkinson disease,” is a rare, chronic, recurrent pustular eruption characterized by subcorneal pustules containing abundant neutrophils. Because SPD pustules usually do not form spongiform structures, the patient’s condition was likely not associated with SPD.

In the present case, because of the close similarities in their cutaneous and histological features, drug-induced pustular eruption and IH could not be distinguished antenatally. The pyrexia, marked edema of the patient’s lower thighs, and the abnormalities of laboratory data could all have been manifestations of the systemic inflammation that occurs in IH. However, the marked improvement of both the cutaneous and biological findings within several days of drug withdrawal strongly indicated the origin of this eruption. At this point, it was still difficult to determine whether the symptom improvement was brought about by drug withdrawal or the resolution of the pregnancy. On the basis of the positive results of the patch test, we finally concluded that her clinical condition was an allergic reaction to ritodrine.

In conclusion, we have reported a case of ritodrine-induced pustular eruptions in a pregnant woman without a history of skin eruptions. In reporting the present case, we emphasize that
ritodrine can cause drug-induced pustular eruptions, which could be misdiagnosed as life-threatening IH.

References


(Received, March 18, 2011)  
(Accepted, May 18, 2011)